Pfizer Vaccine: Everything We Know – How Scientists Decode It



At a time when the coronavirus is sweeping the world in the second wave of the pandemic that proves to be even more deadly than the way, as one country after another proceeds to a lockdown in order to put a brake on the pandemic, the news about the effectiveness of the experimental vaccine by Pfizer (USA) and BioNTech (Germany) raises optimism for the next day. Global optimism The number of new cases and deaths reported daily around the world have caused a global shock as the pandemic seems out of control. Everyone’s eyes have turned to the treatments and the vaccines that are in the final stage. Inside the coronavirus labyrinth, light began to appear in the tunnel after the announcements for the experimental vaccine of Pfizer (USA) and BioNTech (Germany). In particular, as it became known, it seems to be more than 90% effective one week after the second dose, according to a phase 3 clinical trial in 43,538 people, of whom 38,955 have received both doses to date. However, many scientists, despite their obvious or more restrained optimism, do not rush to open champagnes and do not cease to have certain reservations, as questions and doubts remain not only about this vaccine, but also about any others that follow. How long will his protection last, mainly in terms of how long his protection will be, how long it will last and if it will cover all ages equally. “In any case, the vast majority of people will not have access to the vaccine until several months have passed,” says Peter Hotz, a vaccine specialist at Baylor College of Medicine in Texas. “There are still a lot of unanswered questions,” he said. According to APE – Professor Jesse Goodman of Georgetown University in Washington, D.C. -19, the vast majority of which belonged to the control group of volunteers who had received placebo (placebo). The companies did not say exactly how many of the 94 infected had been vaccinated and how many the placebo, but estimated that -with based on the distribution between the two groups (vaccinated and control) – the vaccine is over 90% effective. Tests continueThe trial will continue until 164 cases of Covid-19 are found among those taking part in it, which, according to Pfizer, may have been done by mid-December, when an independent FDA advisory board will recommend whether or not to use Read also: Pfizer vaccine – Next steps – How many doses to take in the EU and GreeceAlthough the vaccine may be less effective when the test is completed and all the data have been analyzed, it is likely that its effectiveness will remain well above 50% which is the minimum acceptable “ceiling” for a vaccine, in order for the FDA to approve its release. The questions about the vaccine Among the questions that remain is whether the vaccine will prevent serious disease and complications of Covid-19 in sick people, how long will the protective immunity last (the head of BioNTech is optimistic that it will last at least a year, but this remains to be confirmed to what extent it will prevent infections or simply reduce the symptoms after infection and also how well it will “work” in the elderly who are the most vulnerable to coronavirus. At present, it is not clear how many elderly people took part in vaccine test and how many got sick. Also, none of the 94 infected appear to have had serious Covid-19, and it is not known how many cases were mild and how moderate. “If a vaccine is going to reduce serious cases and deaths, thus allowing the general population to “It’s going to be effective in the elderly,” said Eleanor Riley, a professor of immunology and infectious disease at the University of Edinburgh. Florian Kramer, a virologist at Mount Sinai Medical School in New York, told Nature that he was among those who volunteered for the experiment. He estimates that by the end of the trial it will be impossible to assess the effectiveness of the vaccine in those over 65 years of age. The vaccine is safe and without side effects Still, the companies have assured that the vaccine is safe and without side effects, but the necessary data for its safety have not been presented yet (it will be done by the end of the month). Also, the two companies have not yet submitted their clinical trial data for evaluation by other scientists, a key step in independently determining the reliability of the findings. Scientists, among other things, want to see to what extent this vaccine prevents completely infection with the new coronavirus or simply reduce the viral load when someone becomes infected. It is also unclear whether the vaccine can prevent people with minimal or minimal Covid-19 symptoms from spreading the coronavirus to a rapid “brake” on the pandemic. “Ideally, we want to have complete protection against the infection, but I think we will accept that these so-called first-generation vaccines are more likely to simply prevent getting sick. But if it does, it will probably still be able to transmit the virus, “said Lawrence Young, a professor at the University of Warwick in the UK.” Right now we need a vaccine that works, even if only for a few months or even if the transmission does not stop. of coronavirus. “This is what we need in order to get back to a semi-normalcy,” said Dr. Kramer. “How long the immunity of the vaccine will last can only be determined by a long-term antibody test on those who got the vaccine, which It is uncertain whether it will be done. In terms of practical difficulties, the innovative type of vaccine (based on mRNA genetic material, something that has never happened before in a vaccine) requires keeping it at a temperature below minus 80 degrees Celsius. This means that even in developed countries – much less in the poor – there will be difficulties in distributing it to millions, if not billions, of people. Pfizer / BioNTech has already produced 500,000 doses of the vaccine and estimates that they will have 50 million ready. by the end of 2020 and up to 1.3 billion in 2021. Optimism by Greek scientists “Light in the tunnel” described the professor of Microbiology and member of the committee of experts of the Ministry of Health, Alkiviadis Vatopoulos, the news about the Pfizer vaccine Speaking to the “MEGA Hour Society”, he stressed that it is a vaccine that is being created for the first time and there are technical difficulties for the subsequent process. “All this must be resolved quickly by the competent authorities,” he pointed out. first doses of vaccine are expected in Greece at the beginning of the year. Infectious disease specialist Marios Lazanas described the results of the Pfizer vaccine against Although Pfizer reports 90% efficiency, it is a huge success. The flu vaccine is 60% effective, and it protects us again. “Lazanas also seems to be doing well in side effects,” Lazanas said. “It is equally important that the vaccine seems to cover the elderly or vulnerable groups who do not have a good ability to produce antibodies. The disadvantage of the new vaccine , he explained, is that it is maintained at -70 or -80 degrees Celsius, as it needs special refrigerators. “Obviously this vaccine cannot be obtained in pharmacies. “It must be approved by the FDA (Food and Drug Administration), and then intensive production will take place.” This vaccine is in two doses, and needs to be repeated in three weeks, “the professor explained to SKAI. Regarding the availability of the vaccine, scientists do not hesitate to say that the procedures are time consuming until the vaccine reaches a large number of people to provide effective protection. At the same time that the Pfizer vaccine will be available for covid-19 in Europe will be available in Greece as well, assured the Deputy Minister of Health Vassilis Kontozamanis. Mr. Kontozamanis explained that in the coming days the agreement between Pfizer and the EU, which includes the supply of the vaccine, will be ratified. As he said, the vaccine is in the process of approval and from the moment it receives it from the competent EU regulatory authorities, its distribution will start. “It is very important that we succeed at the same time that the vaccine will be available in Europe and will be available in Greece,” he said. “All drugs have a long process of verifying efficacy and safety. The difficulty with vaccines is that they require a large number of health products that must be gradually exposed to the virus or the cause. This is a difficulty that takes a long time. Pfizer is the largest pharmaceutical company on the planet. “Dimitris Kouvelas, Professor of Clinical Pharmacology at the Aristotle University of Thessaloniki, told Dimitra Kouvelas, a professor of Clinical Pharmacology at the Aristotle University of Thessaloniki.” Follow it on Google News and be the first to see all news ” the latest News from Greece and the World, at



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *